Adaptive Biotechnologies Stock Price, News & Analysis

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.

Management will engage in a fireside chat on September 10th at 1:05 PM ET. Investors can access both live and archived webcasts of the presentation through the company's website investor section at adaptivebiotech.com.

Adaptive Biotechnologies (Nasdaq: ADPT) reported strong Q2 2025 financial results, with total revenue reaching $58.9 million, a 36% year-over-year increase. The company's MRD business, contributing 85% of revenue, achieved profitability with $1.9 million in Adjusted EBITDA and 42% growth to $49.9 million.

Key highlights include 37% growth in clonoSEQ test volume to 25,321 tests, integration with Flatiron's OncoEMR platform, and implementation of NovaSeq X Plus for clinical sequencing. The company raised its 2025 MRD revenue guidance to $190-200 million and reduced cash burn guidance to $45-55 million.

Despite progress, the company reported a net loss of $25.6 million, though improved from $46.2 million in Q2 2024. Cash position remains strong at $222.0 million as of June 30, 2025.

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has scheduled its Q2 2025 financial results announcement for August 5, 2025 after market close.

The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live webcast through the company's website investor section, with a replay available within 24 hours after the event.

Adaptive Biotechnologies (NASDAQ: ADPT) has announced a strategic integration of its clonoSEQ® test for measurable residual disease (MRD) assessment into Flatiron Health's OncoEMR® platform. The integration provides streamlined access to MRD testing for over 4,500 clinicians across 1,000 community-based cancer care locations in the United States.

The integration, effective July 1, 2025, enables healthcare providers to order and review clonoSEQ MRD testing results directly within the Electronic Medical Record system. This development aims to improve testing workflows and provide real-time insights into patient disease status, particularly for blood cancer patients. The clonoSEQ test helps detect small numbers of cancer cells that may remain during and after treatment, serving as a key predictor of patient outcomes.

Adaptive Biotechnologies (ADPT) announced that its clonoSEQ test for measurable residual disease (MRD) assessment will be featured in 30 scientific presentations at ASCO and EHA 2025 conferences. The presentations include 14 oral presentations showcasing new data supporting clonoSEQ's clinical utility in multiple myeloma and chronic lymphocytic leukemia. Key highlights include the MIDAS phase 3 study of 718 patients demonstrating MRD-guided therapy in multiple myeloma, the ADVANCE phase 2 study with 306 patients showing MRD assessment impact, and the VENETOSTOP trial reporting MRD-guided therapy duration in CLL. Notable studies also showcase clonoSEQ's role in evaluating quadruplet regimens' efficacy in multiple myeloma, including the IsKia, PERSEUS, and DREAMM-8 trials, which demonstrated improved outcomes and higher MRD negativity rates with various treatment combinations.

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on adaptive immune system genetics, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. The company's management will engage in a fireside chat on June 11th at 5:40 a.m. PT / 8:40 a.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website investor section at www.adaptivebiotech.com.

Adaptive Biotechnologies (ADPT) reported strong Q1 2025 financial results with total revenue of $52.4 million, up 25% year-over-year. The company's MRD business, contributing 83% of revenue, grew 34% to $43.7 million, driven by a 36% increase in clonoSEQ test volume to 23,117 tests. Operating expenses decreased 9% to $82.0 million, and net loss improved to $29.8 million from $47.5 million in Q1 2024. The company raised its 2025 MRD revenue guidance to $180-190 million while reducing operating expense guidance to $335-345 million and cash burn target to $50-60 million. Cash position remained strong at $232.8 million as of March 31, 2025.

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on translating adaptive immune system genetics into clinical products, has scheduled its Q1 2025 financial results announcement for May 1, 2025, after market close.

The company will host a conference call and webcast at 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day. Investors can access the live audio webcast through the company's website investor section, with a replay available within 24 hours after the event.

Adaptive Biotechnologies (Nasdaq: ADPT) has secured expanded Medicare coverage for its clonoSEQ® test in mantle cell lymphoma (MCL) surveillance. The coverage now includes single time point testing to monitor disease recurrence in patients during treatment-free remission.

Under the expanded coverage by Palmetto GBA, patients who have completed treatment can receive clonoSEQ testing every six months for up to five years during treatment-free remission, followed by annual testing until disease recurrence. The test pricing is set at $2,007 per test under the Clinical Laboratory Fee Schedule.

MCL, affecting approximately 4,000 new cases annually in the United States, is the first clonoSEQ indication to receive this coverage determination. The test is performed at Adaptive's CLIA-certified lab in Seattle and has received approval from New York State's Clinical Laboratory Evaluation Program.